Techno Medica (6678) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 FY2025 was ¥1,999 million, up 12.9% year-over-year, driven by strong sales of blood collection tube preparation systems and stable consumables demand.

• Operating profit surged 207.2% to ¥250 million, and net profit rose 140.5% to ¥173 million, reflecting higher gross profit and reduced SG&A expenses.

• Overseas sales ratio increased by 3.6 points to 16.8%, with notable growth in Southeast Asia.

Financial highlights

• Gross profit increased 16.1% year-over-year to ¥1,008 million.

• SG&A expenses decreased 3.7% to ¥758 million, mainly due to lower R&D costs.

• Operating margin improved significantly, with operating profit at ¥250 million (207.2% increase) and ordinary profit at ¥255 million (180.3% increase).

• EPS for Q1 was ¥25.10, up from ¥8.75 in the prior year.

Outlook and guidance

• No changes to previously announced forecasts: full-year revenue expected at ¥10,000 million, net profit at ¥970 million, and EPS at ¥124.44.

• Interim and year-end dividends are forecast at ¥68.00 per share, unchanged from prior guidance.